Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study-Reference-Cited by-同舟云学术

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study

Published:2019-08 Issue: Volume:134 Page:174-179
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Dietel M.,Savelov N.,Salanova R.,Micke P.^ORCID,Bigras G.,Hida T.,Antunez J.,Guldhammer Skov B.,Hutarew G.^ORCID,Sua L.F.,Akita H.,Chan O.S.H.,Piperdi B.,Burke T.,Khambata-Ford S.,Deitz A.C.

Funder

Merck Sharp and Dohme

Merck

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung;Janzic;Radiol. Oncol.,2017

2. The next generation of immunotherapy: keeping lung cancer in check;Somasundaram;J. Hematol. Oncol.,2017

3. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer;Reck;Immunotherapy,2018

4. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers;Homet Moreno;Br. J. Cancer,2015

5. Pembrolizumab for the treatment of non–small-cell lung cancer;Garon;N. Engl. J. Med.,2015

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine;Life;2024-09-10

2. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up;Journal of Thoracic Oncology;2024-08

3. Real-World Treatment Patterns and Timeliness of Clinical Care Pathway for Non-Small Cell Lung Cancer Patients in Austria: The PRATER Retrospective Study;Cancers;2024-07-19

4. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer;The Annals of Thoracic Surgery;2024-07

5. A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study;Clinical Lung Cancer;2024-05